Antibodies against the lymphocyte PD-1 (aPD-1) receptor are cornerstone agents for advanced non-small cell lung cancer (NSCLC), based on their ability to restore the exhausted antitumor immune response. Our study reports a novel, lymphocyte independent, therapeutic activity of aPD-1 against NSCLC, blocking the tumor-intrinsic PD-1 receptors on chemoresistant cells.
Novel lymphocyte-independent antitumor activity by PD-1 blocking antibody against PD-1+ chemoresistant lung cancer cells
Rotolo, Ramona;Leuci, Valeria;Donini, Chiara;Galvagno, Federica;Massa, Annamaria;De Santis, Maria Chiara;Peirone, Serena;Medico, Giovanni;Sanlorenzo, Martina;Righi, Luisella;Riganti, Chiara;Salaroglio, Iris Chiara;Napoli, Francesca;Tabbò, Fabrizio;Mariniello, Annapaola;Vigna, Elisa;Modica, Chiara;D'Ambrosio, Lorenzo;Taulli, Riccardo;Hirsch, Emilio;Cereda, Matteo;Aglietta, Massimo;Scagliotti, Giorgio Vittorio;Novello, Silvia;Bironzo, Paolo;Sangiolo, Dario
2023-01-01
Abstract
Antibodies against the lymphocyte PD-1 (aPD-1) receptor are cornerstone agents for advanced non-small cell lung cancer (NSCLC), based on their ability to restore the exhausted antitumor immune response. Our study reports a novel, lymphocyte independent, therapeutic activity of aPD-1 against NSCLC, blocking the tumor-intrinsic PD-1 receptors on chemoresistant cells.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
ccr-22-0761.pdf
Accesso aperto
Tipo di file:
PDF EDITORIALE
Dimensione
1.1 MB
Formato
Adobe PDF
|
1.1 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
